The two firms entered into an initial agreement in early 2020 to use AI in six programs aimed at accelerating the characterization and optimization of mAbs and therapeutic proteins for OSE to investigate as therapeutic agents.

In this new expanded agreement, both companies have reinforced and extended the scope of the collaboration for 10 additional development programs of antibody drugs in immuno-oncology, inflammation, and autoimmune diseases for OSE.

Both companies are also developing a computational in silico antibody discovery and design platform combining OSE's database and expertise with MabSilico's AI-tools. MabSilico's software is being used to guide therapeutic antibody discovery, reduce the risk of failure, and accelerate the preclinical development process of antibody drug candidates, the firms said.